Posts

Oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting: a study protocol for a pilot and definitive randomised double-blind placebo-controlled trial (CannabisCINV).

Authors: Antony J. Mersiades, Annette Tognela, Paul S. Haber, Martin Stockler, Nicholas Lintzeris, et al
BMJ open, 12 September 2018

INTRODUCTION: Chemotherapy-induced nausea and vomiting (CINV) remains an important issue for patients receiving chemotherapy despite guideline-consistent antiemetic therapy. Trials using delta-9-tetrahydrocannabinol-rich (THC) products demonstrate limited antiemetic effect, si…

Safety and Efficacy of Medical Cannabis Oil for Behavioral and Psychological Symptoms of Dementia: An-Open Label, Add-On, Pilot Study

Authors: Assaf Shelef, Yoram Barak, Uri Berger, Diana Paleacu, Shelly Tadger, Igor Plopsky, Yehuda Baruch
Journal of Alzheimer’s Disease, 27 February 2016

BACKGROUND: Tetrahydrocannabinol (THC) is a potential treatment for Alzheimer’s disease (AD). OBJECTIVE: To measure efficacy and safety of medical cannabis oil (MCO) containing THC as an add-on to pharmacotherapy, in relieving behavioral and psychological symptoms of dementia…

Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia

Authors: Sebastian Walther, Richard Mahlberg, Uta Eichmann, Dieter Kunz
Psychopharmacology, May 2006

Nighttime agitation occurs frequently in patients with dementia and represents the number one burden on caregivers today. Current treatment options are few and limited due to substantial side effects. The aim of the study was to measure the effect of the cannabinoid dronabinol…